TRUE-GRIT: Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training

Status: Recruiting
Location: See location...
Intervention Type: Behavioral, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The TRUE-GRIT study will assess the feasibility of a study protocol investigating the efficacy of a combination therapy consisting of cognitive strategy training (CST) and repetitive transcranial magnetic stimulation (rTMS) to reduce cognitive impairment in adult glioma patients. This study is part of the GRIP-project, a project aimed at investigating interventions for improving quality of life in brain tumor patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• ≥ 18 years of age

• Histological diagnosis of diffuse glioma (WHO grade 2,3, or 4)

• Subjective cognitive impairment, defined as CFQ-score ≥ 44

• Being able to give informed consent and undergo treatment and measurements based on researchers insight

• Stable disease, i.e. no oncological treatment for ≤ 2 months prior to inclusion; no radiological progression on the most recent MRI, not older than 6 months, and no clinical progression at inclusion

• Stable dosage (for at least 8 weeks) of anti-epileptic medication

Locations
Other Locations
Netherlands
VU University Medical Centers, location VUmc
RECRUITING
Amsterdam
Contact Information
Primary
Maxine Gorter, MSc
gripopcognitie@amsterdamumc.nl
+31615413273
Time Frame
Start Date: 2024-03-24
Estimated Completion Date: 2026-08
Participants
Target number of participants: 16
Treatments
Experimental: Cognitive strategy training + real rTMS
Verum rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total)
Sham_comparator: Cognitive strategy training + sham rTMS
Sham rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total).
Related Therapeutic Areas
Sponsors
Leads: Linda Douw

This content was sourced from clinicaltrials.gov

Similar Clinical Trials